Half of U.S. adults surveyed say they avoid seeking medical care because of cost, and they want upfront pricing of medical services.
Most American adults believe that healthcare is too expensive, and they want to know the cost of care before receiving treatment. That is the conclusion of a recently released survey by HealthPocket, a Silicon Valley-based tech company and free information source designed to help consumers find medical coverage.
HealthPocket polled 1,100 Americans between the ages of 18 and 64 in November and it was weighted to get representative samples from each state based on population.
The majority (85%) of those surveyed say that healthcare costs in general are too high, and 51% say they have avoided seeking medical care because they lack the ability to pay.
Related: 5 Things Consumers Want From Healthcare
The survey found that prices are a priority, with 91% saying that costs for medical services should be as readily available as prices are on a restaurant menu. In fact, 78% have been afraid to go to the hospital because of cost, with an overwhelming majority (96%) saying that hospitals should be upfront about the cost before treatment. Given the option, 86% said they would compare prices before going to the hospital if prices were posted online.
Four in 10 (41%) of those surveyed say they have been unable to pay a medical bill at some point. Meanwhile, nearly 30% currently have medical debt. When given an option of how medical bills that can't be paid should be handled, 46% believed they should be put on a payment plan; another one in four (25%) said that the government should pay the doctor or hospital; 13% said the debt should just be forgiven; and 12% said volunteer work should be done in exchange for a discount.
The survey also revealed that three in four (73%) Americans don't think that someone should have to declare bankruptcy over unpaid medical bills. When asked if unpaid medical bills should impact one's credit score, a majority (77%) said no. When asked what the best fix is for our healthcare system, only 3% said to leave it as is.
Some other key findings:
The survey can be found at https://www.healthpocket.com/health-insurance-insights/medical-debt-in-us-2019
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More